NeuroNEXT is at your service
Organized after an initial request for applications in 2010, NeuroNEXT was the brainchild of researchers at NIH and several experienced academic investigators. The goal of NeuroNEXT is to streamline clinical therapeutic trials in neurology by organizing academic research sites across the United States. NeuroNEXT includes a Clinical Coordinating Center that manages the participating sites and projects, and a Data Coordinating Center responsible for overseeing data collection, data management, and analysis. Perhaps most importantly, NeuroNEXT also includes a central institutional review board (cIRB) that all participating sites use for approval via a reliance agreement; essentially, the local IRBs cede authority to the cIRB. Having all of these components in place and ready for implementation means that clinical studies can be initiated and performed more quickly and efficiently than would be possible if such an effort were attempted de novo.
At the time of its initial organization, all clinical sites proposing to participate in NeuroNEXT had to prove their worth via a competitive grant application process, explaining what each institution had to offer in terms of clinical trial readiness, the population of patients available for study across the neurological spectrum, past clinical trials experience (both industry and federally sponsored), facilities, and equipment. In addition, institutional support for the idea needed to be demonstrated. In the end, 25 sites across the country were selected to participate, each receiving funds for 5 years to maintain clinical trials readiness. A renewal of the NeuroNEXT site participation is currently underway.
The way in which a new NeuroNEXT study is initiated is fairly straightforward and can be found on the website https://www.neuronext.org. Typically, a researcher proposes to study a specific therapy in a neurological disease and puts together a detailed outline of an experimental plan (termed a “synopsis”); this is reviewed sequentially by a combination of individuals from the National Institute of Neurological Disorders and Stroke and the NeuroNEXT executive committee. If it is considered appropriate for NeuroNEXT, of sufficient priority, and feasible, it is then handed off to a protocol working group that will work with the principal investigator to further refine the idea and help prepare a formal grant application. The grant application is then submitted in the usual fashion to NIH, and undergoes peer and council review to determine eligibility for funding. If it is successful, NeuroNEXT will then assist the investigator in the implementation of the trial.
This issue of Annals of Neurology contains the first completed study from NeuroNEXT, “Natural History of Infantile Onset Spinal Muscular Atrophy.”1 Stephen J. Kolb from the Ohio State University Wexner Medical Center was the principal investigator, and the study was proposed in response to a request for applications issued in 2011 specifically to develop better biomarkers in spinal muscular atrophy (SMA). The study included 15 NeuroNEXT sites and focused on infants with the most severe forms of the disease presenting before 6 months of age. A group of healthy infants were also enrolled and followed for 2 years. All children underwent a number of assessments at baseline and every 6 months for 2 years.